A Novel TRAF3IP2 Mutation Causing Chronic Mucocutaneous Candidiasis

Area of Science:

• Immunology
• Genetics
• Dermatology

Background:

• Interleukin-17 (IL-17) mediated signaling is crucial for host defense against fungal infections, particularly Candida species.
• Inborn errors affecting the IL-17 pathway are known causes of chronic mucocutaneous candidiasis (CMC).

Observation:

• A patient presented with a complex phenotype including CMC, atopic dermatitis, enamel dysplasia, and recurrent parotitis.
• Genetic analysis revealed a novel compound heterozygous mutation in the TRAF3IP2 gene in the affected individual.

Findings:

• The identified mutation resulted in autosomal recessive ACT1 deficiency, a critical component of the IL-17 receptor complex.
• This deficiency led to impaired IL-17 signaling, explaining the susceptibility to mucocutaneous candidiasis and other associated symptoms.

Implications:

• This case expands the spectrum of genetic defects causing CMC and highlights the importance of ACT1 in immune regulation.
• Understanding this novel mutation provides insights into IL-17 pathway function and potential therapeutic targets for related immunodeficiencies.